In today’s podcast, ASCO’s Chief Medical Officer, Dr. Richard Schilsky, discusses ASCO’s first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry, or TAPUR Study. The TAPUR Study is a clinical trial for people with later-stage cancer, focused on whether specific targeted therapies can benefit more patients and lead to more personalized treatments.  Dr. Schilsky explains the objectives of the study, and provides information about who might be eligible to participate, as well as what is involved. Cancer Research News